The
global Blood Cancer Diagnostics Market size is expected
to reach USD 16.04 billion by 2030, registering a CAGR of 6.87% from 2025 to
2030, according to a new report by Grand View Research, Inc. The market is
driven by the increasing incidence of blood malignancies, such as leukemia,
lymphoma, and myeloma. The market is further expected to grow significantly due
to the increasing elderly population, which is more susceptible to chronic
diseases, including blood cancer. In addition, technological advancements,
including NGS and other molecular diagnostic techniques, are improving the
accuracy & efficiency of diagnosis, which is likely to drive the market
over the forecast period.
Over the past
decade, significant advancements have been made in approaches to blood cancer
diagnostics, all aimed at reducing the growing incidence of diseases and their
mortality. While these advancements have been well-documented to increase early
cancer detection, there have been considerable advancements. For instance, NGS has
enabled the analysis of the entire genome of cancer cells, providing insights
into genetic mutations that guide precise diagnosis and tailored treatments. In
October 2022, OGT, a Sysmex group, introduced a range of new offerings to
augment its expanding NGS product suite. Notably, the SureSeq Myeloid Plus
panel was designed to identify genetic mutations associated with various
Myeloid disorders, enhancing the company’s capabilities in this critical area
of research.
Molecular
imaging techniques, such as SPECT/CT, PET, and flow cytometry, utilize
molecular imaging agents to detect indicative molecular markers at different
disease stages, aiding detection & monitoring. Such advancements in imaging
technologies offer improved accuracy and early detection capabilities, driving
the market. The global players are introducing automatic imaging tests and
systems to boost their market share. For instance, in May 2023, Sysmex
Corporation announced the launch of the Clinical Flow Cytometry System in
Japan. The system includes Flow Cytometer XF-1600, Sample Preparation System
PS-10, antibody reagents, and other related products. This system enables laboratories
to automate the entire process of flow cytometry testing, from sample
preparation to the reporting of measurement results, contributing to higher
efficiency & testing standardization.
Governments
across the world have recognized the immense healthcare burden posed by rising
incidences, including hematological malignancies such as leukemia &
lymphoma. In response, many countries have launched comprehensive national
cancer control programs that prioritize early detection and screening efforts.
For instance, the American Association of Cancer Research recently launched the
Beau Biden Cancer Moonshot initiative to accelerate cancer research and make
preventive screening more accessible & affordable for U.S. citizens.
Some of the
key players in the market are Illumina, InVivoScribe, Ipsogen (Qiagen),
Asuragen(Bio-Techne), Danaher Corporation, Abbott, SkylineDx, Adaptive
Technologies, Bio-Rad Laboratories and others. These players are involved in
various strategic initiatives such as product launch and approval in order to
cater to a global clientele. For instance, in September 2023, Adaptive
Technologies launched Epic integration for clonoSEQ, a molecular diagnostic
test for MRD monitoring in blood cancers. This integration allows healthcare
providers to order and review clonoSEQ test results directly within Epic's EHR
system, streamlining clinical decision-making and improving patient care.
List
of Key Players in the Blood Cancer Diagnostics Market
- Quest Diagnostics
- Illumina
- InVivoScribe
- Ipsogen (Qiagen)
- Asuragen(Bio-Techne)
- Danaher Corporation
- Abbott
- Sequenta (Adaptive
biotechnologies)
- SkylineDx
- Bio-Rad Laboratories
- Alercell
- Sophia Genetics
Request a free sample copy or view report
summary: Blood Cancer Diagnostics Market Report
Blood
Cancer Diagnostics Market Report Highlights
- Based on product, the
assay kits and reagents accounted for the largest revenue share of the
blood cancer diagnostics market in 2024. This high share is attributable
to assay kits & reagents being designed to detect specific biomarkers,
genetic mutations, and other indicators, enabling healthcare professionals
to diagnose & treat the disease more effectively
- Based on tests, blood
tests segment dominated the market and accounted for the largest share in
2024. This can be attributed to increasing innovation and availability of
blood test kits for blood cancer detection
- Based on end use,
hospitals and clinics dominated the market with the largest share of blood
cancer diagnostics market in 2024. This is attributable to growing demand
in forensic labs and hospital medical labs for disease diagnosis, blood
cell counts, blood typing. Furthermore, Developments in hospital
laboratories are crucial to address the evolving needs of patients, and
more hospitals aim to provide a wide range of services in their settings
- North America
dominated the market due to the presence of a large number of major market
players, North America has a high prevalence of chronic diseases like
leukemia These diseases require regular monitoring and diagnostic testing,
fueling the demand for advanced diagnostic tools and technologies
- Asia Pacific is
expected to witness the fastest growth over the forecast period from 2025
to 2030, due to the presence of manufacturers with innovative devices
manufacturing capabilities coupled with accelerated diagnostic research
capabilities
Blood
Cancer Diagnostics Market Segmentation
Grand View
Research has segmented the global blood cancer diagnostics market based on
product, test, end-use, and region:
Blood
Cancer Diagnostics Product Outlook (Revenue, USD Million, 2018 - 2030)
- Instruments
- Assay Kits and
Reagents
Blood
Cancer Diagnostics Test Outlook (Revenue, USD Million, 2018 - 2030)
- Blood Tests
- Imaging Tests
- Biopsy
- Molecular Test
Blood
Cancer Diagnostics End Use Outlook (Revenue, USD Million, 2018 - 2030)
- Hospitals and Clinics
- Diagnostic Labs
- Research Institutes
Blood
Cancer Diagnostics Regional Outlook (Revenue in USD Million, 2018 - 2030)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Sweden
- Denmark
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East and Africa
- Saudi Arabia
- South Africa
- UAE
- Kuwait
About Us
Grand
View Research, Inc. is a U.S. based market research and consulting company, registered
in the State of California and headquartered in San Francisco. The company
provides syndicated research reports, customized research reports, and
consulting services. To help clients make informed business decisions, the
company offers market intelligence studies ensuring relevant and fact-based
research across a range of industries including technology, chemicals,
materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
No comments:
Post a Comment